Evidence for efficacy is based on the results from the CADENZA study
Home World News FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy
Evidence for efficacy is based on the results from the CADENZA study
